The cellular oncogene EWS/activating transcription factor 1 is unable to activate adenovirus-borne promoters: Implications for cytotoxic prodrug therapy of malignant melanoma of soft parts

Cancer Gene Therapy

Volumn 7, Issue 3, 2000, Pages 396-406

  Lung, Raymond W M ^a   Lee, Kevin A W ^a  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

Adenovirus; EWS ATF1 oncogene; Gene therapy; Malignant melanoma of soft parts

Indexed keywords

ANTIVIRUS AGENT; COMPLEMENTARY DNA; CYTOTOXIC AGENT; GANCICLOVIR; PRODRUG; RNA; SOMATOSTATIN; TRANSCRIPTION FACTOR; VIRUS VECTOR;

ADENOVIRUS; ARTICLE; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; MELANOMA; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; VIRUS INFECTION; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADENOVIRIDAE; HERPES; SIMPLEXVIRUS;

EID: 0034072968     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700142     Document Type: Article

References (63)

1. Rabbitts TH. Chromosomal translocations in human cancer. Nature. 1994;372:143-149.
2. Ladanyi M. The emerging molecular genetics of sarcoma translocations. Diagn Mol Pathol.. 1994;4:162-173.
3. Zucman J, Delattre O, Desmaze C, et al. EWS and ATF1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat Genet. 1993;4:341-345.
4. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992;359:162-165.
5. May WA, Gishizky ML, Lessnick SL, et al. Ewings sarcoma 11-22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by fli1 for transformation. Proc Natl Acad Sci USA. 1993;90:5752-5756.
6. May WA, Lessnick SL, Braun BS, et al. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol. 1993;13:7393-7398.
7. Zucman J, Melot T, Desmaze C, et al. Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J. 1993;12:4481-4487.
8. Sorenson PHB, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, Denny CT. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet. 1994;6:146-151.
9. Ladanyi M, Gerald W. Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumour. Cancer Res. 1994;54:2837-2840.
10. Chung EB, Enzinger FM. Malignant melanoma of soft parts. Am J Surg Pathol. 1983;7:405-413.
11. Epstein AL, Martin AO, Kempson R. Use of a newly established human cell line (SU-CCS-1) to demonstrate the relationship between clear cell sarcoma to malignant melanoma. Cancer Res. 1984;44:1265-1274.
12. Hicks MJ, Saldivar VA, Chintagumpala MM, Cooley LD. Malignant melanoma of soft parts involving the head and neck region: review of literature and case report. Ultrastruct Pathol. 1995;19:395-400.
13. Caraway NP, Fanning CV, Wojcik EM, Staerkel GA, Benjamin RS, Ordonez NG. Cytology of malignant melanoma of soft parts: fine-needle aspirates and exfoliative specimens Diagn Cytopathol. 1993;9:632-638.
14. Kim J, Lee KAW, Pelletier J. The desmoplastic small round cell tumor t(11;22) translocation produces EWS/ WT1 isoforms with differing oncogenic properties. Oncogene. 1998;16:1973-1979.
15. Braun BS, Frieden R, Lessnick SL, May WA, Denny CT. Identification of target genes for the Ewing's sarcoma EWS/FLI fusion protein by representational difference analysis. Mol Cell Biol. 1995;15:4623-4630.
16. Thompson AD, Braun BS, Arvand A, et al. EAT-2 is a novel SH2 domain-containing protein that is up-regulated by Ewing's sarcoma EWS/FLI1 fusion gene. Oncogene. 1996;13:2649-2658.
17. Karnieli E, Werner H, Rauscher FJ III, Benjamin LE, LeRoith D. The IGF-1 receptor gene promoter is a molecular target for the Ewing's sarcoma-Wilms' tumor 1 fusion protein. J Biol Chem. 1996;271:19304-19309.
18. May WA, Arvand A, Thompson AD, Braun BS, Wright M, Denny CT. EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic. Nat Genet. 1997:17:495-497.
19. Watson DK, Robinson L, Hodge DR, Kola I, Papas TS, Seth A. FLI1 and EWS-FLI1 function as ternary complex factors and ELK1 and SAP1a function as ternary and quaternary complex factors on the Egr1 promoter serum response elements. Oncogene. 1997;14:213-221.
20. Lee SB, Kolquist KA, Nichols K, et al. The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour. Nat Genet. 1997;17:309-313.
21. Ouchida M, Ohno T, Fujimura Y, Rao VN, Reddy ESP. Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts. Oncogene. 1995;11:1049-1054.
22. Kovar H, Aryee DNT, Jug G, et al. EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth and Differ. 1996;7:429-437.
23. Yi H-K, Fujimura Y, Ouchida M, Prasad DDK, Rao VN, Reddy ESP. Inhibition of apoptosis by normal and aberrant Fli-1 and erg proteins involved in human solid tumors and leukemias. Oncogene. 1997;14:1259-1268.
24. Tanaka K, Iwakuma T, Harimaya K, Sato H, Iwamoto Y. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J Clin Invest. 1997;99:239-247.
25. Lee KAW, Masson N. Transcriptional regulation by CREB and its relatives. Biochim Biophys Acta. 1993;1174: 221-233.
26. Ribeiro A, Brown AD, Lee KAW. An in vivo assay for members of the CREB family of transcription factors. J Biol Chem. 1994;269:31124-31128.
27. Huber BE, Richards CA, Krenitsky TA. Retroviral gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc Natl Acad Sci USA. 1991;88:8039-8043.
28. Harris JD, Gutierrez AA, Hurst HC, Sikora K, Lemoine NR. Gene therapy for cancer using tumour-specific pro-drug activation. Gene Ther. 1994;1:170-175.
29. Harris JD, Lemoine NR. Strategies for targeted gene therapy. Trends Genet. 1996;12:400-405.
30. Brown AD, Lopez-Terrada D, Denny CT, Lee KAW. Promoters containing ATF-binding sites are de-regulated in cells that express the EWS/ATF1 oncogene. Oncogene. 1995;10:1749-1756.
31. Fujimura Y, Ohno T, Siddique H, Lee L, Rao VN, Reddy ESP. The EWS-ATF-1 gene involved in malignant melanoma of soft parts with t(12;22) chromosome translocation encodes a constitutive transcriptional activator. Oncogene. 1996;12:159-167.
32. Pan S, Koh YM, Dunn TA, Li KKC, Lee KAW. The EWS/ATF1 fusion protein contains a dispersed activation domain that functions directly. Oncogene. 1998;16:1625-1631.
33. Yeh P, Perricaudet M. Advances in adenoviral vectors: from genetic engineering to their biology. FASEB J. 1997; 11:615-623.
34. Anderson WF. Human gene therapy. Nature. 1998;392:25-30.
35. Kaneko S, Hallenbeck P, Kotani T, et al. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res. 1995;55:5283-5287.
36. Wills KN, Huang W-M, Harris MP, Machemer T, Maneval DC, Gregory RJ. Gene therapy for hepatocellular carcinoma: chemosensitivity conferred by adenovirus-mediated transfer of the HSV-1 thymidine kinase gene. Cancer Gene Ther. 1995;2:191-197.
37. Hall SJ, Mutchnik SE, Chen SH, Woo SLC, Thompson TC. Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer. Int J Cancer. 1997;70:183-187.
38. Montminy MR, Sevarino KA, Wagner JA, Mandel G, Goodman RH. Identification of a cyclic-AMP-responsive element within the rat somatostatin gene. Proc Natl Acad Sci USA. 1986;83:6682-6686.
39. Gorman CM, Merlino GT, Willingham MC, Pastan I, Howard BH. The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection. Proc Natl Acad Sci USA. 1982;79:6777-6781.
40. Tsukada T, Fink JS, Mandel G, Goodman RH. Identification of a region in the human vasoactive intestinal polypeptide gene responsible for regulation by cyclic AMP. J Biol Chem. 1987;262:8743-8747.
41. Weeks DL, Jones NC. Adenovirus E3-early promoter: sequences required for activation by E1A. Nucleic Acids Res. 1985;13:5389-5402.
42. Belt AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertion or deletions in early regions 1 and 3. Proc Natl Acad Sci USA. 1994;91:8802-8806.
43. Hearing P, Shenk T. The adenovirus type 5 E1A transcriptional control region contains a duplicated enhancer element. Cell. 1983;33:695-703.
44. Kohler PO, Bridson WE. Isolation of hormone-producing clonal lines of human choriocarcinoma. J Clin Endocrinol Metab. 1971;32:683-687.
45. Gorman CM, Moffat LF, Howard BH. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol. 1982;2:1044-1051.
46. Lee KAW, Green M. A cellular transcription factor E4F1 interacts with an E1A-inducible enhancer and mediates constitutive enhancer function in vitro. EMBO J. 1987;6: 1345-1353.
47. Ido A, Nakata K, Kato Y, et al. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human α-fetoprotein gene promoter. Cancer Res. 1995;55: 3105-3109.
48. Lee KAW, Hai T-Y, Siva-Raman L, et al. A cellular protein, activating transcription factor, activates transcription of multiple E1A-inducible adenovirus early promoters. Proc Natl Acad Sci USA. 1987;84:8355-8359.
49. Sassone-Corsi P. Cyclic AMP induction of early adenovirus promoters involves sequences required for E1A trans-activation. Proc Natl Acad Sci USA. 1988;85:7192-7196.
50. Lee KAW, Fink JS, Goodman RH, Green MR. Distinguishable promoter elements are involved in transcriptional activation by E1A and cyclic AMP. Mol Cell Biol. 1989;9:4390-4397.
51. Li KKC, Lee KAW. MMSP tumor cells expressing the EWS/ATF1 oncogene do not support cAMP-inducible transcription. Oncogene. 1998;16:1325-1331.
52. Kanai F, Shiratori Y, Yoshida Y, et al. Gene therapy for α-fetoprotein-producing human hepatoma cells by adeno-virus-mediated transfer of the herpes simplex virus thymidine kinase gene. Hepatology. 1996;23:1359-1368.
53. Osaki T, Tanio Y, Tachibana I, et al. Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res. 1994;54:5258-5261.
54. Lan KH, Kanai F, Shiratori Y, et al. Tumor-specific gene expression in carcinoembryonic antigen-producing gastric cancer cells using adenovirus vectors. Gastroenterology. 1996;111:1241-1251.
55. Tanaka T, Kanai F, Okabe S, et al. Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-produring human gastric carcinoma cells in vitro. Cancer Res. 1996;56:1341-1345.
56. Chatterjee PK, Vayda ME, Flint SJ. Adenoviral protein VII packages viral DNA throughout the early phase of infection. EMBO J. 1986;5:1633-1644.
57. Matsumoto K, Okuwaki M, Kawase H, Handa H, Hanaoka F, Nagata K. Stimulation of DNA transcription by the replication factor from the adenovirus genome in a chromatin-like structure. J Biol Chem. 1995;270:9645-9650.
58. Gao GP, Yang Y, Wilson JM. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol. 1996;70:8934-8943.
59. Dedieu JF, Vigne E, Torrent C, et al. Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. J Virol. 1997;71:4626-4637.
60. Clemens PR, Kochanek S, Sunada Y, et al. In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. Gene Ther. 1996;3:965-972.
61. Chen HH, Mack LM, Kelly R, Ontell M, Kochanek S, Clemens PR. Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci USA. 1997; 94:1645-1650.
62. Bertolotti A, Melot T, Acker J, Vigneron M, Delattre O, Tora L. EWS, but not EWS-FLI-1, is associated with both TFIID and RNA polymerase II: interactions between two members of the TET family, EWS and hTAFII68, and subunits of TFIID and RNA polymerase II complexes. Mol Cell Biol. 1998;18:1489-1497.
63. Petermann R, Mossier BM, Aryee DN, Khazak V, Golemis EA, Kovar H. Oncogenic EWS-Fli1 interacts with hsRPB7, a subunit of human RNA polymerase II. Oncogene. 1998;17:603-610.